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Thoracic endovascular repair as a safe management
strategy for aortobronchial fistulas
Charles J. Bailey, MD, Seth Force, MD, Ross Milner, MD, Karthikeshwar Kasirajan, MD, and
Ravi K. Veeraswamy, MD, Atlanta, Ga
Objectives: This study assessed the safety and efficacy of thoracic endovascular aortic repair (TEVAR) in the management
of aortobronchial fistulas.
Methods: A retrospective review was performed at Emory University Hospital to identify all patients who presented with
an aortobronchial fistula. The diagnosis was based on clinical, radiologic, and bronchoscopic findings. Patients who
underwent TEVAR as definitive management of these fistulas were identified. Demographics, history of thoracic aorta
pathology or intervention, type and number of endografts used, need for reoperation, and clinical and radiologic
follow-up data were collected for each individual.
Results: Between 2000 and 2009, 11 patients received TEVAR as definitive management of aortobronchial fistulas.
Technical success was achieved in 10 patients (91%). Six patients (55%) had previously undergone thoracic aortic surgery.
A proximal type 1 endoleak developed in one patient after graft deployment and required reintervention for additional
graft placement. No intraoperative or 30-day deaths occurred. Postoperative clinical and radiographic assessment was a
mean of 8.8 months (range, 1-40 months). For all 10 patients in whom technical success was achieved at the initial
operation, no endoleaks were noted at the follow-up CT scan. In addition, no patient required a further intervention.
Conclusions: This study represents the largest reported series on the use of TEVAR in the management of aortobronchial
fistulas. Supported by postoperative surveillance imaging and clinical evaluation, TEVAR has proven to be a safe and
effective management strategy for an otherwise lethal condition. Long-term follow-up data are needed to ascertain the
durability of this approach. (J Vasc Surg 2011;53:1202-9.)
n
a
S
d
a
t
f
c
d
m
p
r
e
s
m
l
m
M
v
a
o
D
o
d
H
t
wAortobronchial fistulas (ABFs) are communications be-
tween the thoracic aorta and the adjacent tracheobronchial
system.1 During the last century, ABFs have been associ-
ated with a number of thoracic aorta pathologies, including
atherosclerotic aneurysms of the descending thoracic aorta,
anastomotic pseudoaneurysms occurring subsequent to
previous open aortic surgery, mycotic aneurysms, traumatic
thoracic aorta injuries, and even in the setting of penetrat-
ing aortic ulcers.1-14 Hemoptysis, either intermittent or
massive, remains the most common presenting symptom of
ABF.3 For the patient with documented aortic pathology
and hemoptysis, a high level of clinical suspicion is neces-
sary to expedite management. These fistulas are uniformly
lethal if left untreated.1,15 Successful management man-
dates prompt diagnosis and definitive treatment to achieve
favorable clinical outcomes.
Operative management of ABF has traditionally en-
tailed open surgical repair of the thoracic aorta with recon-
struction of the involved bronchial tree. Such open tech-
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1202iques are associated with high perioperative morbidities
nd a reported surgical mortality of 15% to 41%.3,16-18
uccessful endovascular stent graft repair of ABF was first
escribed in 1996 in separate reports from Campagna et
l19 and Chuter et al.20 With refinement of endovascular
echniques, TEVAR now represents an operative approach
or ABF with potentially reduced morbidity and mortality
ompared with standard open surgical repair. However,
ebate exists about the role of TEVAR in ABF manage-
ent. Opinions vary about whether the endovascular ap-
roach serves as definitive management, a bridge to open
epair, or should not be considered as a repair strategy.21
The aim of our study was to further examine the
fficacy of TEVAR for ABF. A retrospective review of our
ingle-institution experience with TEVAR in the manage-
ent of ABFs was performed. This study represents the
argest reported series on the use of TEVAR for manage-
ent of ABFs.
ETHODS
A retrospective review was performed at Emory Uni-
ersity Hospital to identify all patients who presented with
n admission diagnosis of aortobronchial, aortopulmonary,
r aortobronchopulmonary fistula from January 2000 to
ecember 2009. Institutional Review Board approval was
btained before review of all relevant patient records, and
ata were maintained in a database compliant with the
ealth Insurance Portability and Accountability Act. Pa-
ients who underwent TEVAR for management of ABF
ere further identified.
Analyzed data included patient age, gender, thoracicortic pathologies, previous thoracic aortic surgery, dura-
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Volume 53, Number 5 Bailey et al 1203tion from previous thoracic aortic surgery, preoperative
radiologic and bronchoscopic findings, and the type and
number of endograft components used. Measured out-
comes centered on intraoperative mortality, 30-daymortal-
ity, hospital and intensive care unit (ICU) length of stay,
length of clinical and radiologic follow-up as measured in
months, postprocedural radiologic findings, need for rein-
tervention after the initial TEVAR, postoperative respira-
tory or renal failure, and ABF recurrence. Also reported
were perioperative and postoperative antibiotic usage as
well as results of admission and postprocedural complete
blood count (CBC), basic metabolic panel (BMP), and
microbiologic tests.
RESULTS
From January 2000 to December 2009, 19 patients
were diagnosed and treated for aortobronchial fistula
(ABF); of these, 11 (58%) underwent TEVAR for ABF
management, and 8 (42%) received traditional open repair
of the fistula tract. Demographics and clinical characteris-
tics of the patients receiving TEVAR are presented in Table
I. Patients were a mean age of 69.8 years (range, 30-89
years) at presentation. Gender of patients was evenly repre-
sented, with five women (45%) and six men (55%) treated.
The 11 patients presented with a chief complaint of
hemoptysis. Six (55%) had undergone previous thoracic
aortic surgery, with five of six (83%) patients having under-
gone more than one aortic surgical procedure. The previ-
ous thoracic aorta interventions of these six patients in-
cluded: aorta to left subclavian artery bypass for aortic
coarctation in three (50%), with two of the patients receiv-
ing a second operation for treatment of the coarctation;
open traumatic thoracic aorta repair in one (17%), with this
patient also requiring reoperation for definitive repair of the
traumatic aortic injury; and, open descending thoracic an-
eurysm repair in two (33%); again, one patient underwent
re-operation for definitive repair of the thoracic aneurysm.
Table I. Patient demographics
Patient Age Sex Diagnosis Bronchosco
1 88 F DTA with leak, LLL atelectasis . . .
2 89 F PAU, left pleural effusion . . .
3 72 F PAU with PA . . .
4 82 M Anastomotic erosion Superior LL
5 54 M DTA, left HTX Superior LL
6 83 M DTA . . .
7 58 M DTA with mycotic PA LLL
8 52 M DTA Lateral LLL
9 30 M Anastomotic erosion Posterior L
10 85 F Aortic arch PA Not visuali
11 75 F DTA, ruptured . . .
AAA, Abdominal aortic aneurysm; Ao-L SCA, aorta to left subclavian artery
LUL, left upper lobe; PA, pseudoaneurysm; PAU, penetrating aortic ulcer;
aYears between prior aortic surgeries and TEVAR for ABF.Themean interval between the initial thoracic aorta surgery pnd the diagnosis of the ABF was 20 years (range, 6-30
ears).
Computed tomography angiography (CTA) was per-
ormed for all patients as part of the hospital admission
iagnostic workup. Radiologic diagnoses in the 11 patients
ncluded descending thoracic aneurysm in 6 (55%), pene-
rating aortic ulcer in 2 (18%), anastomotic erosion of
revious bypass graft in 2 (18%), and aortic arch pseudoan-
urysm in 1 (9%). Six patients (55%) also underwent pre-
perative bronchoscopy. In 5 (83%) patients, the origin of
he intrabronchial hemorrhage, defined as the presence of
ctive hemorrhage or clotted blood, was visualized in the
uperior left-lower lobe in 2 (40%), the posterior left-upper
obe in 1 (20%), the lateral left-lower lobe in 1 (20%), and
eft-lower lobe (exact segment not identified) in 1 (20%).
Eleven patients underwent TEVAR for management
f ABF. The diagnosis of ABF was confirmed in all 11
atients after intraoperative angiography. The ABFs in-
olved varying levels of the aorta, including the follow-
ng Ishimaru aortic zones: five (45.5%) in zone 4, five
45.5%) in zone 3, and one (9%) in zone 1. The sites of
ascular access, type of endograft used, and the number
nd sizes of deployed components are presented in Table
I. The TAG endograft (W. L. Gore and Assoc, Flagstaff,
riz) was used in 10 of 11 patients (91%). One patient
eceived a Talent endograft (Medtronic AVE, Santa
osa, Calif) for ABF coverage.
Nine of 11 patients (82%) underwent open common
emoral artery exposure for sheath delivery. In one individ-
al, the caliber of the external iliac artery was too small to
ccommodate the delivery sheath, necessitating anastomo-
is of a 10-mmDacron graft to the left common iliac artery
or vascular access.
Management of the left subclavian artery (LSCA) in the
1 patients included the following: in 8 (73%) the LSCA
as not involved and remained patent; in 2 (18%), the
SCA was covered without symptoms of ischemia. One
Past aortic surgery Timea
None . . .
None . . .
None . . .
Coarctation, s/p Ao-L SCA bypass 27 year
Traumatic aorta injury, s/p open aortic repair  2 29 year
AAA, s/p open aneurysm repair 16 year
DTA, s/p open repair  2 14 year
None . . .
Coarctation, s/p Ao-L SCA bypass  2 30, 12 year
Coarctation, s/p Ao-L SCA bypass  2 22 year
None —
DTA, s/p open repair 6 year
AAA, s/p open repair 4 year
, descending thoracic aneurysm; HTX, hemothorax; LLL, left lower lobe;
atus post; TEVAR, thoracic endovascular aneurysm repair.py
L
L
UL
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; DTAatient required coil embolization of LSCA for persistent
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May 20111204 Bailey et altype II endoleak. The orifice of the LSCA in one patient
was partially covered, without ischemic symptoms after the
procedure.
Eight patients with ABF were managed exclusively by
the thoracic surgery service. Four (50%) were treated non-
operatively, and four (50%) received traditional open repair
of the fistula tract. Patients in the nonoperative group
elected no surgical intervention given their extensive med-
ical comorbidities and a heightened risk of perioperative
complications.
A 50% in-hospital mortality rate was observed in the
nonoperative patients after two patients died secondary
to intrabronchial hemorrhage. Traditional open surgical
repair of the aorta that involved the lung parenchyma was
associated with an intraoperative mortality rate of 50% (2
of 4), and a 30-day postoperative mortality of 100%
(4 of 4).
Clinical end points and outcomes of the patients receiv-
ing TEVAR are presented in Table III. Technical success
was achieved in 10 of 11 patients (91%) at the initial
operation, as verified by intraoperative angiography. The
interval from diagnosis of ABF to TEVAR averaged 4 days
after hospital admission (range, 0-17 days). No intraoper-
ative or 30-day deaths were observed. Length of stay was a
mean of 12.5 days (range, 4-32 days) in the hospital and 6
Table II. Operative technique
Patient Endografta No.b Sizes Access
1 TAG 2 40 mm  20 cm Retroperitoneal
conduit37 mm  15 cm
2 TAG 1 26 mm  10 cm Common femoral
artery
3 TAG 2 28.5 mm  3.3 cm Common femoral
artery28.5 mm  3.3 cm
4 TAG 5 23 mm  3.3 cm Percutaneous
common
femoral artery
26 mm  3.3 cm
26 mm  3.3 cm
28.5 mm  3.3 cm
28.5 mm  3.3 cm
5 TAG 1 31 mm  15 cm Common femoral
artery
6 Talent 3 46 mm  16 cm Common femoral
artery46 mm  16 cm
46 mm  11 cm
7 TAG 2 31 mm  15 cm Common femoral
artery34 mm  15 cm
8 TAG 1 28 mm  10 cm Common femoral
artery
9 TAG 2 28.5 mm  3.3 cm Common femoral
artery28.5 mm  3.3 cm
10 TAG 1 34 mm  15 cm Common femoral
artery
1 36 mm  10 cm Common femoral
artery
11 TAG 2 34 mm  15 cm
40 mm  15 cm Common femoral
artery
aTAG, W. L. Gore & Associates, Flagstaff, Ariz; Talent, Medtronic AVE,
Santa Rosa, Calif.
bNumber of endostent components deployed.days (range, 1-32 days) in the intensive care unit. Labora- Cory analysis at admission showed a mean leukocytosis of
1.47  103 mm (range, 6.3-25.9  103/mm3) and an
verage baseline creatinine value of 1.14 mg/dL (range,
.6-1.7 mg/dL).
Postoperative clinical and radiologic follow-up aver-
ged 8.8 months after TEVAR (range, 1-40 months). In all
1 patients, no additional hemoptysis or recurrence of ABF
as noted postoperatively. Further, for the 10 patients in
hom technical success was achieved at the initial opera-
ion, no additional endovascular interventions were re-
uired postoperatively. Two patients did undergo separate
horacic procedures after successful endostent placement.
horacotomy, evacuation of hemothorax, lung decortica-
ions, and wedge resection of the pulmonary end of the
stula tract were performed in these individuals.
Microbiologic tests, including cultures of blood and
rine specimens, were collected preoperatively on two pa-
ients due to presence of fevers or leukocytosis, or both.
nly 2 of the 11 patients (18%) managed with TEVAR
ere prescribed extended courses of antibiotics postopera-
ively:
Patient 5 was admitted to the hospital with a leukocy-
osis value of 26  103 mm, and a large left hemothorax.
perative procedures included TEVAR for management of
he ABF and a separate thoracic procedure for evacuation
f hemothorax, lung decortication, and wedge resection of
he involved lung parenchyma. This patient received a
-week course of prophylactic intravenous levofloxacin
iven the associated finding of hemothorax adjacent to the
ortic endostent. This individual remained afebrile
hroughout the hospital stay, with no organism growth in
lood, sputum, or pleural fluid cultures.
Patient 7 presented to our institution with fevers and a
ocumented methicillin-resistant Staphylococcus aureus
MRSA) bacteremia. This individual had undergone cho-
ecystectomy at another hospital 2 weeks before admission
o our institution, with the postoperative course compli-
ated by cardiac arrest and development of MRSA bactere-
ia. Repeat blood cultures at our hospital showed persis-
ence of theMRSA bacteremia, with the pathogen sensitive
o vancomycin. A 6-week course of intravenous vancomy-
in was prescribed due to the heightened risk of endostent
nfection in the setting of bacteremia.
Patient 10 required an additional endovascular inter-
ention postoperatively consequent to progression of a
roximal type I endoleak experienced at the initial TE-
AR. She presented to our institution with a 3-week
istory of intermittent hemoptysis, dyspnea, and chest
ain. CTA revealed a large saccular aneurysm of the
ortic arch involving the orifice of the left common
arotid and subclavian arteries. The presence of hemop-
ysis led to the clinical suspicion of an ABF. A carotid-
o-carotid arterial bypass and TEVAR were performed,
ut a proximal type I endoleak persisted after endostent
eployment. No further hemoptysis, cerebral ischemic
vents, or left arm neuromuscular deficits were noted
ostoperatively. However, postoperative surveillance
TA did reveal a significant proximal type I endoleak, as
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Reoperation was performed 38 months later. Placement
of an additional TAG endograft proximally failed to
obliterate the type I endoleak. The type II endoleak was
managed successfully with combined coil embolization
and an Amplatzer plug (AGA Medical Corp, Plymouth,
Minn) occlusion of the LSCA.
Lastly, one inpatient death occurred after TEVAR in a
30-year-old man who presented with hemoptysis, hemor-
rhagic shock, and respiratory distress. Twenty-two years
prior he had undergone two separate aorta-to-subclavian
artery bypasses for repair of aortic coarctation. Bronchos-
copy revealed hemorrhage within the posterior left upper
lobe, with clinical and radiographic data supportive of acute
respiratory distress syndrome. TEVAR was performed suc-
cessfully on the day of admission. This patient remained
Fig 1. Preoperative computed tomography angiography
(white arrow), and (B) evidence of aneurysm rupture wi
Table III. Clinical end points
Patient Delay (day)a LOS (day)b F/u (Month)c A
1 6 8 2 No
2 0 4 20 No
3 6 13 14 No
4 17 23 2 No
5 0 11 3 Levofloxacin: 750
6 1 3 6 No
7 1 6 1 Vancomycin: 1.75
8 0 6 2 No
9 1 32 1 No
10 12 16 40 No
11 0 16 6 No
ABF, Aortobronchial fistula; LSCA, left subclavian artery; PO, per os.
aNumber of days between diagnosis and treatment of ABF.
bLength of hospital stay, measured in days.
cLength of clinical and radiologic follow-up, measured in months.ventilator-dependent throughout the postoperative period, tequiring tracheostomy. He also experienced worsening
enal insufficiency postoperatively, with serum creatinine
levating from 1.3 to 2.5 mg/dL. Despite all resuscitative
easures, he died of hypoxic respiratory failure 32 days
ostoperatively.
ISCUSSION
Left untreated, ABF is a uniformly fatal condition with
reported mortality of 100%.1,3,15 Prompt diagnosis and
xpedient operative management are key prognostic factors
n survival of an ABF.15 Hemoptysis remains the most
ommon presenting symptom. The diagnostic challenge of
his condition is heightened by lack of a radiologic or
ndoscopic test to accurately demonstrate a fistulous con-
ection. CTA may demonstrate pathology of the thoracic
orta and adjacent lung tissue, but a fistulous communica-
s (A) a saccular aneurysm of the proximal thoracic aorta
diastinal hematoma formation.
otics ABF recurrence Reoperation
No None
No None
No None
No None
O qday (6 weeks) No None
No None
q12 hours (6 weeks) No None
No None
No None
No 38M postop-
Type I endoleak, proximal;
TAG placement
Type II endoleak, LSCA;
Amplatzer plug
No Noneshowntibi
mg P
g i.v.ion is rarely ever visualized. Fig 1 presents the CTA of a
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hemoptysis. Although thoracic pathologies of hemothorax,
pleural effusion, or atelectasis were identified adjacent to
the aforementioned vascular pathologies, no definitive fis-
tula tracts were visualized on CTA.
Bronchoscopy is the most sensitive and specific method
for visualization of the source of hemoptysis, yet it is
underused for fear of dislodging clots overlying the fistula
tract, thus inciting further hemorrhage.3,22 Fig 2 shows an
ABF detected during bronchoscopy of the patient noted in
Fig 1. Fig 3 displays intraoperative fluoroscopy before and
after endostent deployment for this patient.
A high index of clinical suspicion remains essential for
the timely and accurate diagnosis of ABF. Hemoptysis in a
patient with thoracic aorta pathology is highly suggestive of
ABF and should lead the clinician to pursue urgent opera-
tive repair.
Historically, definitive management of ABF has en-
tailed open surgical repair of both the aortic and pulmonary
components to the fistula.1,3 Performed through a left
posterolateral thoracotomy, open surgical repair involves
cross-clamping of the descending thoracic aorta, direct
repair or arterial bypass of the aortic defect, with concom-
itant resection or reconstruction of involved bronchial seg-
ments. The morbidity of open repair is multifactorial;
the emergent nature of repair, the risks of aortic cross-
clamping, and the technical challenges of aortic exposure in
patients who have previously undergone thoracotomy for
aortic repair all increase the perioperative morbidity. Fur-
ther, despite advances in surgical techniques, published
reports estimate the operative mortality of open ABF repair
to range from 15% to 41%.3,16-18 The results of TEVAR as
definitive management for ABF have been more favorable.
A review of the literature from 1947 through 2002
Fig 2. Preoperative bronchoscopy demonstrates aortobronchial
fistula (black arrow) at the distal left main-stem (LMS) bronchus.identified 76 patients with ABF.3 Of these patients, 52 deceived conventional open repairs with an overall mortality
f 15%. Comparatively, 15 individuals underwent TEVAR
ith a lower overall mortality of 6%. In further support of
n endovascular repair, a meta-analysis by Jonker et al23 of
1 patients who underwent TEVAR for ABF reported a
echnical success rate of 90%, with only 3% in-hospital
ortality.
Our study represents the largest single-institution ex-
erience with TEVAR in management of ABF. The char-
cteristics and diagnostic workup of our patients mirror
hose reported in similar case reports and meta-analy-
es.24-34 Notably, our treatment group had a nearly even
istribution of men and women, all patients presented with
emoptysis, and each received a CT as part of the initial
iagnostic work-up. Though CTA was successful in dem-
nstrating thoracic aortic pathology and adjacent lung
arenchymal changes, no ABF were visualized as a direct
esult of this diagnostic test.
Six of the 11 patients further received flexible bron-
hoscopy to assist in diagnosis. Bronchoscopic examination
as successful in diagnosing ABF in five of six patients
83%), with active hemorrhage or formed clots visualized in
he bronchial tree. Our success in diagnosing ABF with
exible bronchoscopy validates this modality as a useful
djunct to the diagnostic workup.22
Lastly, our series reaffirms the association of ABF with
rior thoracic aortic intervention.1,3,6,9,12,35-37 Six patients
55%) had undergone prior thoracic aortic procedures,
ith three of these (50%) involving arterial bypasses for
oarctation of the aorta. The literature review of Picichè et
l3 confirms the increased prevalence of ABF after aortic
oarctation repair, noting 26 of the 71 (37%) described
BFs to occur in this specific postoperative state. The
linical characteristics alone illustrate that hemoptysis in a
atient with thoracic aorta pathology or prior intervention
s highly suggestive of ABF, warranting expedient definitive
anagement given the lethality of the condition.
The patient in our series who required repeat interven-
ion incurred an endoleak subsequent to anatomic con-
traints encountered during TEVAR. This 85-year-old
oman presented with hemoptysis and CTA found a pseu-
oaneurysm of the aortic arch. Given her medical comor-
idities, open aortic repair was deemed unsafe and an
ndovascular approach was performed. Adequate coverage
f the proximal extent of the ABF required extension of the
ndostent proximal to the orifice of the left common ca-
otid artery, thus necessitating a carotid-to-carotid arterial
ypass. A rather acute angulation of the aortic arch resulted
n a proximal type I endoleak, which persisted despite serial
ilatations and additional stent placements. Surveillance
maging in the postoperative period showed an interval
ncrease of the pseudoaneurysm as well as a type II endoleak
rom the LSCA. Repeat intervention at 38 months postop-
ratively included an additional stent graft placement prox-
mally as well as coil embolization and occlusion plug to the
SCA, which were still unsuccessful in treating the en-
oleak. This was our only treatment failure.
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in management of ABF.21,38,39 Chiesa et al39 reported the
results of a national survey examining the utility of TEVAR
in management of both aortobronchial and aortoesopha-
geal fistula. In 25 of 1138 patients (2.2%), TEVAR was
indicated for treatment of aortoesophageal or aortobron-
chial fistula, or both. An ABF was present in only 12 of
1138 (1.1%) of these individuals. Operative management
consisted of TEVAR alone in 15 patients, with a combined
endovascular and open bronchial or esophageal procedure
performed in the remaining 10. Results of the TEVAR-
alone group showed a 30-day mortality of 40%, overall
mortality at follow-up of 53%, and late TEVAR failure
occurring in five individuals (28%). The study reached the
consensus that TEVAR alone does not afford complete and
lasting cure for ABF and aortoesophageal fistula. However,
the results of this study are limited by lack of a true subset
analysis. The TEVAR alone group is not stratified by diag-
nosis, thus not accurately reflecting the outcomes of pa-
tients with solely ABF.
Comparatively, our experience demonstrates clinical
outcomes supportive of endovascular repair in manage-
ment of ABF. Analysis of patient characteristics and clinical
outcomes illustrated a 91% technical success at initial oper-
ation, no intraoperative or 30-day deaths, no recurrence of
hemoptysis, no late TEVAR failure, as monitored through
postoperative surveillance CT, no clinical or radio-
graphic evidence of endostent infection, and one reinter-
vention for persistent proximal type I endoleak after the
original TEVAR.
The success of such interventions can be attributed to
the extensive endovascular experience at our institution as
well as to the timely diagnosis and short interval to opera-
tive repair. In our series, the interval from presentation of
hemoptysis to diagnosis and subsequent repair of ABF with
TEVAR was an average of 4 days after hospital admission
(range, 0-17 days). In addition, 7 of the 11 patients (64%)
underwent TEVAR 24 hours of admission. Few studies
report the interval from diagnosis of ABF to operative
Fig 3. A, Intraoperative fluoroscopy of pre-endostent
aortobronchial fistula (circle). B, Post-endostent imagi
extravasation through the aortobronchial fistula.repair. Some studies have even reported delays as great as 6 ponths from the initial episode of hemoptysis until the
iagnosis of ABF.40 Considering the high mortality of
BF, our prompt diagnosis and repair seems prognostic for
mproved outcomes.
Infection of prosthetic thoracic endostents is a signifi-
ant concern, particularly in the setting of ABF. A number
f reports on the endovascular repair of ABF comment on
he necessity, duration, and method of delivery of periop-
rative antibiotics.6,11,16,20,40,41 A review of the published
ase series and meta-analyses shows a consensus has not
een reached on the role of antibiotics. Most authors
ould agree that extended courses of antibiotics are war-
anted in the setting of bacteremia or other systemic infec-
ions as prophylaxis against endostent infection. However,
consensus statement on a best-practice antibiotic regimen
as not been reported. Our practice has been to adopt a
onservative approach to antibiotic use, similar to that
eported by Riesenman et al.41 All patients receive three
oses of intravenous perioperative cephalosporin, with
ong-term regimens reserved for those with documented
acteremia or ABF occurring secondary to mycotic aneu-
ysms. As our results show, selective use of extended anti-
iotics resulted in no postoperative endostent infections to
ate.
Our study has several limitations. First, our results
eflect the clinical outcomes of a single-center series. The
ethal nature and infrequent occurrence of the condition
ay preclude blinded, randomized-controlled trials com-
aring open with endovascular repair, although certainly
ore data on the use of TEVAR would be beneficial.
Second, our study lacks measures of long-term end
oints. Postoperative clinical and radiographic follow-up
ssessment averaged 8.8 months (range, 1-40 months).
ur follow-up is also less than ideal because our patients are
rawn from a large geographic area and often will stop
oming to our tertiary care facility due to inconvenience.
ttempts were made to contact patients in this study, and
ur presented data reflect the best follow-up we could
btain. Our series, and results of similar scope, show very
yment illustrates extravasation of contrast through the
cuments coverage of aneurysm, without endoleak ordeplo
ng doromising early results, although little is known of the
11
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tional studies, whether randomized or retrospective, will
clarify the validity of TEVAR for management of ABF.
CONCLUSIONS
The lethality of ABFs mandates prompt diagnosis and
therapy. With refinement of endovascular surgical tech-
niques, TEVAR has been applied to this rare condition.
The results of multiple case series on the use of TEVAR as
definitive management of ABF have demonstrated techni-
cal successes and reduced mortality rates superior to con-
ventional open repair. Tenets of management include
maintaining a high index of suspicion for the vascular
patient with hemoptysis, urgent repair, bronchoscopy as a
useful adjunct to diagnosis, and selective use extended
antibiotic regimens. With further reported experiences, the
long-term durability of TEVAR in ABF management will
be better understood.
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the antibiotics. How many patients were on antibiotics for 6, 8, 12
weeks? And if so, which antibiotics? I couldn’t quite read your slide.
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Dr Michael Singh (Rochester, NY). The authors have deter-
mined that thoracic endovascular aneurysm repair (TEVAR) for aor-
tobronchial fistulas (ABFs) is technically feasible and has acceptable
short-term results. In 9 years, 19 cases presented at your institution,
and 11 underwent endovascular repair. Of the 11 cases, computed
tomography (CT) imaging was performed preoperatively, which de-
fined aortic pathology but failed to diagnose the fistula. Six of 11
underwent bronchoscopy, with the origin of bleeding located in five
of six patients. My questions are: How was the aortobronchial fistula
diagnosismade in the six patientswhodid not undergo bronchoscopy
or had a negative endoscopy? In an era of advanced endovascular
therapy, can you explainwhy stacked abdominal aortic cuffs were used
in three patients? In reviewing your manuscript, 8 of 11 patients were
followed for a time frame of 6months or less. Do you have any recent
data on these patients, specifically looking at mortality and the occur-
rence of graft infections?
Dr Charles J. Bailey. For the six individuals who did not have
ABF diagnosed with bronchoscopy, looking back through the case
series, these are often patients who are not admitted primarily to
the vascular or thoracic surgery service. There is a fair number that
were admitted to the medical service. So the index of suspicion is
not there. And I think for the six that once they are brought to the
consultation of our service, given the fact that they had docu-
mented CT angiography, they have thoracic pathology, the pres-
ence of ongoing hemoptysis not explained otherwise, I think it was
purely clinical suspicion that led to the diagnosis. And certainly if
you look after TEVAR, the hemoptysis is resolved, I guess in
hindsight it was an accurate judgment.
Secondly, for the stacked aortic cuffs, one thing that Pachucki
had mentioned in his work, in looking back at the progression of
these ABFs, is you have one episode of hemoptysis and the track
stays a certain size. And as these events progress, or if they are
unrecognized, that defect enlarges. And I think Dr Veeraswamy
could comment better on the necessity of putting multiple stents
in. I think it was to adequately cover not only the defect but to
ensure there was not an endoleak at completion.
We do not have any additional follow-up than we reported
here. But certainly long-term follow-up will be needed to validate
this as an effective therapy.
Dr Anil Hingorani (Brooklyn, NY). I wanted to ask you aboutDr Bailey. There was a preface to that, kind of the regimen or
he protocol that is used once we have determined there is ABF is
ll patients receive perioperative cephalosporins. All patients get
urveillance blood cultures prior to stent deployment. Two pa-
ients were on long-term antibiotics, meaning6 weeks, one with
methicillin-resistant Staphylococcus aureus (MRSA) bacteremia,
he second one who had a vent-associated pneumonia. The MRSA
as treated with vancomycin. The vent-associated pneumonia was
reated with Levaquin for 6 weeks duration.
We have maintained a selective antibiotic regimen, meaning
hat unless there is documented bacteremia or another source of
epsis, the patients are not routinely sent home on prolonged
egimens of antibiotics. And to this point we don’t have any
ocumented evidence of end ostent infection.
Dr Hingorani. I would find that troubling, because there are
ome case reports in the literature with aortoenteric fistulas that
ere not put on antibiotics for long-term, permanent in some
ases, where they ended up with reinfections and having to have
einterventions, which are disastrous. That was, I guess, based
pon your infectious disease consult perhaps?
Dr Bailey:Correct. A combination of that and if you look at the
eports, though limited, when broaching the topic of long-term
ntibiotics, most studies have felt that the flora in the pulmonary
ystem ismarkedly less thanwith an aortoenteric fistula and that without
ocumented sources they didn’t feel compelled to treat them.
Dr Ravi Veeraswamy. We were sort of surprised when we
ooked back that this is what the data had shown. I think one of the
hings that we are hypothesizing is that we had a very short delay
etween the time of diagnosis and the placement of the stent graft.
nd you could theorize that maybe we were able to seal it sooner and
o on.
The other reason we didn’t put them on long-term antibiotics
as it was very unclear in conjunction with our infectious disease
olleagues exactly what we would use and what the optimal therapy
ould be. And so as this sort of developed, the first couple of patients
ere not put on antibiotics and they did okay for 1 month and 3
onths and 6 months and so on, so we adopted that algorithm. But
t is something thatwe are looking atwith each case that comes in, and
ertainly I would agree with you that it is surprising.
And then just to clarify the answer to Michael, we did see the
stula ultimately when we did the angiogram. The point is that we
idn’t see it preprocedurally.
